NCT06215638

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are: * Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis? * Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis? Participants will: * Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total. * Follow-up at weeks 4, 12, and 24, while biosamples will be collected.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Bortezomib	Bortezomib 2 mg per week subcutaneously, for twelve weeks in total

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-06-30
• Completion: 2024-12-30
• First posted: 2024-01-22
• Last updated: 2024-01-22

Locations

1 site across 1 country: China